Humulin N (Insulin Human (Rdna))

Humulin N is prescribed to help control hyperglycemia in diabetes patients.

• As basal insulin in a basal‑bolus regimen for type 1 diabetes.
• As part of a mixed insulin regimen for type 2 diabetes when oral agents are insufficient.
• To provide long‑acting insulin coverage overnight and between meals.
• For patients requiring a stable, predictable insulin profile with reduced risk of rapid peaks.
• When a suspension formulation is preferred for gradual absorption.
• In combination with rapid‑acting insulin analogues to achieve full basal‑bolus coverage.

• Humulin N delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the intracellular tyrosine‑kinase cascade, promoting translocation of GLUT‑4 transporters to the cell surface, which increases glucose uptake. In the liver, the signal suppresses gluconeogenesis and glycogenolysis while enhancing glycogen synthesis, thereby lowering circulating blood glucose levels. The prolonged suspension formulation allows a gradual release, providing basal insulin activity over many hours.

Like other insulin products, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, tremor, confusion or loss of consciousness.
• Redness, swelling, or itching at the injection site.
• Lipodystrophy, including lipoatrophy or lipohypertrophy at repeated injection sites.
• Weight gain due to increased caloric storage.
• Transient visual disturbances, especially during rapid glucose changes.

Serious

• Severe hypoglycemia requiring assistance from another person.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Insulin‑induced edema or fluid retention.
• Electrolyte disturbances, notably hypokalemia.
• Hypersensitivity leading to serum sickness‑like reactions.

When prescribing or using Humulin N, clinicians and patients should observe several precautionary measures to minimize risks and ensure optimal glycemic control.

• Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance.
• Adjust dose during periods of illness, stress, or changes in physical activity to avoid hypo‑ or hyperglycemia.
• Monitor blood glucose frequently, especially when starting treatment or modifying the regimen.
• Educate patients on proper injection technique and site rotation to reduce local reactions.
• Review concomitant medications that affect glucose metabolism, such as corticosteroids or beta‑blockers.

Humulin N may interact with other agents that influence blood glucose levels or insulin pharmacodynamics, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• Administration of meglitinides or sulfonylureas together without careful monitoring, increasing risk of low blood glucose.
• Combining with high‑dose glucocorticoids that markedly raise glucose, potentially overwhelming insulin effect.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; patients should monitor glucose closely.
• ACE inhibitors or ARBs can potentiate insulin’s glucose‑lowering effect, requiring dose titration.
• Alcohol intake can unpredictably affect glucose; caution is advised when drinking.